Literature DB >> 35480518

Predictive value of serum adiponectin and hemoglobin levels for vascular cognitive impairment in ischemic stroke patients.

Zhouling Li1, Manlian Zhu2, Cheng Meng3, Hai Lin4, Lifen Huang5.   

Abstract

Objectives: To investigate the potential predictive value of serum adiponectin (APN) and hemoglobin (Hb) levels for the occurrence of vascular cognitive impairment in ischemic stroke patients.
Methods: Eighty ischemic stroke patients, admitted to our hospital between June 2019 and November 2020, were retrospectively divided into no cognitive impairment (NCI) group (n=43) and cognitive impairment (CI) group (n=37) based on Montreal Cognitive Assessment (MoCA) scale scoring at three months follow-up. ELISA was used to assess serum Hb and APN levels and receiver operating characteristic (ROC) curves were created to evaluate correlation.
Results: Serum APN and Hb levels were lower in the vascular cognitive impairment group compared to non-impaired counterparts. Pearson correlation analysis showed that both APN and Hb levels were positively correlated with MoCA scores. Area under curve analysis indicated predictive value for serum APN and Hb for predicting cognitive impairment in ischemic stroke patients.
Conclusion: Serum APN and Hb levels in ischemic stroke patients have value for predicting vascular cognitive impairment and may be suitable for helping dictate treatment planning. Copyright: © Pakistan Journal of Medical Sciences.

Entities:  

Keywords:  Adiponectin; Hemoglobin; Ischemic stroke; Vascular cognitive impairment

Year:  2022        PMID: 35480518      PMCID: PMC9002452          DOI: 10.12669/pjms.38.3.5204

Source DB:  PubMed          Journal:  Pak J Med Sci        ISSN: 1681-715X            Impact factor:   1.088


INTRODUCTION

Ischemic stroke incidence is high in the Chinese elderly population, as is mortality and disability rate. Current evidence suggests that 25–30% of ischaemic stroke patients develop vascular cognitive impairment or vascular dementia.1,2 Early diagnosis and intervention can effectively delay or prevent vascular cognitive impairment from developing into vascular dementia.3,4 Vascular dementia pathogenesis involves oxidative stress responses, which can be detected by measuring serum hemoglobin (Hb) levels.5 Moreover, adiponectin (APN) has been recently found to improve vascular dementia in patients with atherosclerosis, glucose metabolism disorder, and hypertension.6 However, the value of serum APN and Hb levels for predicting vascular cognitive impairment in ischemic stroke patients has not been investigated. This study examined the serum APN and Hb levels of 80 ischemic stroke patients and used this data to examine the relationship between these parameters and vascular cognitive impairment probability.

METHODS

For this retrospective study, medical records of ischemic stroke patients hospitalized between June 2019 and November 2020 in the Second People’s Hospital of Li Shui were evaluated, and 80 patients were included in the study. Study protocol was approved by the ethics committee of the Second People’s Hospital of Li Shui (No. 2021012).

Inclusion criteria:

Stroke onset time within 24 hours. Ischemic stroke was diagnosed in accordance with the 2014 Chinese National Guidelines for the Diagnosis of Acute Ischemic Stroke.7 The patient had no prodromal symptoms before onset, and the cognitive function, motor function and social adaptability were at a normal level.

Exclusion criteria:

Patients with a modified Rankin score8 under 5 points. Patients with other severe medical diseases such as liver/kidney failure and acute myocardial infarction. Patients with hearing impairment, visual impairment, dysarthria, aphasia, or other symptoms preventing the independent completion of the cognitive function evaluation. Patients with Hamilton Depression Scale9 scores equal or greater than 8. Brain tumor patients. Patients with connective tissue, rheumatic, immune, or infectious diseases. Patient with cognitive impairment prior to ischemic stroke.

Additionally, exclusion criteria during the follow-up period included:

Patients diagnosed with serious diseases (such as myocardial infarction or severe trauma) during the follow-up period. Patients who were unwilling to continue the study or who were withdrawn by their families. Patients who suffered another ischemic stroke. Patients who died or were not followed-up.

Detection of Serum APN and Hemoglobin

For all hospitalized ischemic stroke patients, fasting venous blood (3-4 ml) was collected on the morning of the day after admission. Collected blood was centrifuged at 3000 rpm for 10 minutes to separate and collect upper serum, which was stored at -20°C. Serum levels of Hb and APN were detected using immunofluorescence assay (ELISA) according to manufacturer’s instructions.

Patient Follow-Up

All patients, included in the study, had records of the follow-up assessment three months after treatment, where their cognitive function was evaluated using the Montreal Cognitive Assessment Scale (MoCA).10 by two neurologists. Based on the recorded data, patients with MOCA scores greater or equal to 23 (of a maximum of 30) were retrospectively assigned to the no cognitive impairment (NCI) group (n = 43), while those with scores under 23 were assigned to the cognitive impairment (CI) group (n = 37).

Observation Indices were as follows

basic patient data, collected during hospitalization, including age, gender, chronic diseases (atrial fibrillation, chronic obstructive pulmonary disease, hyperlipidemia, and coronary heart disease), smoking, drinking, and education level. Homocysteine (Hcy), high-sensitivity C-reactive protein (hs CRP), and systolic blood pressures (SBP) were also recorded. Hyperlipidemia was defined as low density lipoprotein (LDL) ≥ 3.37 mmol/l, triglyceride levels ≥ 1.70 mmol/l, or serum total cholesterol ≥ 5.18 mmol/l. Drinking was defined as consuming alcohol at least once a week over a period of six months. Smoking was defined as one cigarette per day over a period of six months. Homocysteine levels ≥ 15 mmol/l were considered as elevated, with blood hypersensitive C-reactive protein levels > 3 mg/l considered elevated.

Data Analysis

All data were analyzed by SPSS 20.0 software. For data expressed as mean ± SD, t-tests were used to examine relationships between groups. Chi square tests were used when data was expressed as percentages. Pearson correlation analysis was used to analyze correlations between serum APN, Hb, and MOCA scores. Receiver operating characteristic curves (ROC) were used to evaluate the diagnostic ability of APN and Hb for vascular cognitive impairment after ischemic stroke. Logistic regression analysis was used to analyze influencing factors for vascular cognitive impairment in ischemic stroke. P < 0.05 indicated statistical significance.

RESULTS

Serum APN and Hb levels in patients in the CI group were lower than those without vascular cognitive impairment (NCI group, P < 0.05, Table-I). Pearson correlation analysis showed that serum APN and Hb levels were positively correlated with MOCA score (r = 0.447 and 0.452, respectively, P < 0.01).
Table I

Serum APN and Hb levels in patients with and without vascular cognitive impairment.

GroupnAPN(mg/L)HB(g/L)
CI group375.38±2.74102.53±12.36
NCI group439.39±2.41136.48±10.38
T6.9613.35
P0.000.00

NCI, no cognitive impairment; CI, cognitive impairment.

Serum APN and Hb levels in patients with and without vascular cognitive impairment. NCI, no cognitive impairment; CI, cognitive impairment. The area under the curve (AUC) for the serum APN and Hb ROC curves for the diagnosis of vascular cognitive impairment in patients with ischemic stroke were 0.768 (95% Cl: 0.652-0.881) and 0.782 (96% Cl: 0.672-0.884), respectively (Fig.1). This showed positive significance for predicting vascular cognitive impairment in patients with ischemic stroke (P < 0.05).
Fig.1

ROC curve analysis.

ROC curve analysis. Univariate analysis showed that serum VPN, Hb, Hcy, hs CRP, and SBP were associated with vascular cognitive impairment in patients with ischemic stroke (P < 0.05). Atrial fibrillation, chronic obstructive pulmonary disease, hyperlipidemia, coronary heart disease, smoking, drinking, educational level, age, and gender were not associated (P > 0.05, Table-II). Logistic regression analysis showed that serum APN, Hb levels, and homocysteine were independent risk factors for vascular cognitive impairment in patients with ischemic stroke (P < 0.05, Table-III).
Table II

Single factor analysis.

GroupCI groupNCI groupt/χ2P
Number of cases3743
Age65.38±8.9364.92±9.310.220.823
GenderMale19210.05
Female1822
Education levelPrimary school and below11130.028
Junior high school and senior high school1719
Junior college or above911
Drink wineYes12140
No2529
SmokeYes13160.037
No2427
Systolic blood pressure ≥ 140 mmHgYes23147.011
No1429
Coronary heart diseaseYes12170.434
No2526
HyperlipidemiaYes18200.036
No1923
Chronic obstructive pulmonary diseaseYes7100.224
No3033
Atrial fibrillationYes9130.348
No2830
High sensitivity C-reactive protein increasedYes28207.048
No923
Elevated homocysteineYes27921.763
No1034
APN(mg/L)5.38±2.749.39±2.416.96
HB(g/L)102.53±12.36136.48±10.3813.35

NCI, no cognitive impairment; CI, cognitive impairment; APN, adiponectin; Hb, hemoglobin.

Table III

Multivariate analysis.

ItemΒS.E.WaldX²POR95%CI
APN-0.7140.2647.3150.0070.4900.2920.822
HB-0.8130.23112.3870.0000.4440.2820.698
Systolic pressure0.7830.4752.7170.0992.1880.8625.551
High sensitivity C-reactive protein0.9890.5183.6450.0562.6890.9747.421
Homocysteine1.4650.5936.1030.0134.3281.35413.836

APN, adiponectin; Hb, hemoglobin.

Single factor analysis. NCI, no cognitive impairment; CI, cognitive impairment; APN, adiponectin; Hb, hemoglobin. Multivariate analysis. APN, adiponectin; Hb, hemoglobin.

DISCUSSION

This study showed that serum APN and Hb levels in ischemic stroke patients with vascular cognitive impairment were lower than patients with no cognitive impairment. Recent epidemiological studies have suggested an increase in the incidence of ischemic stroke in China, which leads to an increased prevalence of varying degrees of vascular cognitive impairment and dementia.11–13 Clinically, motor dysfunction is the primary concern when treating ischemic stroke patients. However, more data is showing that improving cognitive function is very important for functional recovery and quality of life.14,15 APN is a very active adipocyte secretory factor that combines with receptors AdipoR1 and R2 to exert its biological functions.16–18 Previous studies that have found that neurodegenerative diseases, cardiovascular diseases, hypertension, diabetes, abnormal lipid metabolism, obesity, and other diseases are closely related to APN levels.19–21. APN and its receptors are abundantly expressed in the brain and may have a crucial effect on cognitive function. However, there is still no consensus on the correlation between APN levels and cognitive function. Studies by Kamogawa et al. and Une et al. showed that increased plasma APN levels were associated with better cognitive function in males, but not in females. Roberts et al. found no significant difference in circulating APN levels was visible between mild cognitive impairment patients and controls. In contrast, Teixeira et al. reported that in patients with mild CI and Alzheimer’s disease, low circulating APN levels were associated with cognitive dysfunction.22 Their conclusions are in agreement with the results of our study that in ischemic stroke patients low APN levels correlate with lower cognitive function. Anemia and overall decreased Hb levels reported in up to 40% of patients with acute ischemic stroke.23–25 Studies indicate that decreased Hb levels lead to increased oxidative stress in neuronal cells and subsequent cognitive dysfunction.26 A current systemic review and meta-analysis found a direct association between anemia and cognitive function deterioration and dementia in older patients > 65 years old.27,28 In addition to elevated oxidative stress, decreased Hb levels also promotes hypoxia by lowering blood oxygen capacity.29,30 Anemia can also induce oxidative stress through endothelial damage.31,32 In our study, decrease in Hb level was strongly associated with the decrease in cognitive function of patients in the CI group as compared to patients without cognitive impairment. Pearson correlation analysis in our study showed that in ischemic stroke patients, the serum APN and Hb levels were positively correlated with MOCA scores, indicating a linear relationship between serum APN and Hb levels and vascular cognitive impairment severity. Finally, ROC analysis showed that both serum APN and Hb levels had a better predictive function for predicting vascular cognitive impairment in patients with ischemic stroke, but that the AUC for serum Hb was larger than that for serum APN, indicating that serum Hb levels are a better predictive indicator than serum APN levels.

Limitations of the study

This study has several limitations. There was no long-term follow-up information, nor was there any dynamic observation of serum APN and Hb levels over time. As such, we believe that these findings need to be further confirmed via a long-term longitudinal study with a larger sample size.

CONCLUSIONS

The data presented here indicates that serum APN and Hb levels correlate with the development and severity of vascular cognitive impairment in ischemic stroke patients. Therefore, these values may be predictive for vascular cognitive impairment, and can be used for optimizing interventional strategies.

Authors’ contributions:

ZL: Conceived and designed the study and is responsible for integrity of the study. MZ, CM & HL: Collected the data and performed the analysis. ZL: Was involved in the writing of the manuscript. LH: Data analysis, interpretation, Edited the manuscript. All authors have read and approved the final manuscript.
  30 in total

1.  Cerebral vascular accidents in patients over the age of 60. II. Prognosis.

Authors:  J RANKIN
Journal:  Scott Med J       Date:  1957-05       Impact factor: 0.729

2.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

3.  Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease.

Authors:  Antonio L Teixeira; Breno S Diniz; Alline C Campos; Aline S Miranda; Natalia P Rocha; Leda L Talib; Wagner F Gattaz; Orestes V Forlenza
Journal:  Neuromolecular Med       Date:  2012-09-28       Impact factor: 3.843

Review 4.  Anaemia and cognitive performances in the elderly: a systematic review.

Authors:  M Andro; P Le Squere; S Estivin; A Gentric
Journal:  Eur J Neurol       Date:  2013-05-06       Impact factor: 6.089

5.  Safety profile of high molecular weight polymerized hemoglobins.

Authors:  Cynthia R Muller; Alexander T Williams; Carlos J Munoz; Allyn M Eaker; Amanda N Breton; Andre F Palmer; Pedro Cabrales
Journal:  Transfusion       Date:  2020-10-26       Impact factor: 3.157

6.  Alzheimer and vascular dementia in the elderly patients.

Authors:  Naresh Kumar Seetlani; Narindar Kumar; Khalid Imran; Asif Ali; Nadia Shams; Taha Sheikh
Journal:  Pak J Med Sci       Date:  2016 Sep-Oct       Impact factor: 1.088

7.  Association of serum adiponectin with breast cancer: A meta-analysis of 27 case-control studies.

Authors:  Zeping Yu; Shenli Tang; Hongbing Ma; Hong Duan; Yong Zeng
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

Review 8.  Stroke injury, cognitive impairment and vascular dementia.

Authors:  Raj N Kalaria; Rufus Akinyemi; Masafumi Ihara
Journal:  Biochim Biophys Acta       Date:  2016-01-22

9.  Decreased hemoglobin as a quantifiable indicator of renal arterial embolization in post-percutaneous nephrolithotomy hemorrhage.

Authors:  Ruitu Ran; Ruiyuan Zhang; Ye Xie; Zhikang Yin
Journal:  Urolithiasis       Date:  2020-08-08       Impact factor: 3.436

10.  Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study.

Authors:  Linxin Li; Gabriel S Yiin; Olivia C Geraghty; Ursula G Schulz; Wilhelm Kuker; Ziyah Mehta; Peter M Rothwell
Journal:  Lancet Neurol       Date:  2015-07-27       Impact factor: 59.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.